A randomized controlled, open‐label early phase II trial comparing incidence of FOLFIRI.3‐induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer. - Yamazaki, Kaori; Ariyoshi, Noritaka; Miyauchi, Hideaki; Ohira, Gaku; Kaneya, Noriko; Yamamoto, Kohei; Arai, Kenichi; Yamazaki, Shingo; Matsubara, Hisahiro; Suzuki, Takaaki; Ishii, Itsuko (Journal of Clinical Pharmacy & Therapeutics, 2019)